AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them

CME Available: https://auau.auanet.org/node/43041

At the conclusion of this activity, participants will be able to:

1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer.

2. Risk-stratify patients with non muscle- invasive bladder cancer.

3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin.

4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease.

5. Individualize patient surveillance according to risk stratification.

6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management.

ACKNOWLEDGEMENTS

This educational activity is supported by an independent educational grants from:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.